Experimental validation is urgently needed, particularly in IDH-mutant low-grade glioma cell lines, to assess PpIX accumulation and fluorescence following combined exposure to 5-ALA and vorasidenib. This evidence concerns the gene IDH1 and central nervous system cancer.